文献速递膀胱癌与上尿路尿路上皮癌

开放与机器人辅助根治性膀胱切除术的肿瘤学结局随机试验

Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes.
PubMed 文献 · Eur Urol · 2018-05-18

该前瞻性随机试验于2010-2013年纳入118例膀胱癌患者,随机接受开放或机器人辅助根治性膀胱切除术加盆腔淋巴结清扫,均行开放/体外尿流改道。中位随访4.9年,两组在复发、癌症特异性生存和总生存上无显著差异,但首次复发模式存在差异,且试验把握度不足以检测肿瘤学结局差异。

要点

  • 两组复发风险无显著差异(HR 1.27,95%CI 0.69-2.36,P=0.4)。
  • 癌症特异性生存和总生存无显著差异(P=0.4和P=0.8)。
  • 开放手术组转移部位复发风险非显著升高(sHR 2.21,95%CI 0.96-5.12,P=0.064),机器人组局部/腹部复发风险更高(sHR 0.34,95%CI 0.12-0.93,P=0.035)。

核心结论

  • 随机试验的次要结局未明确显示开放与机器人辅助根治性膀胱切除术在肿瘤学结局上的差异。
  • 观察到的首次复发模式差异提示需要未来研究进一步验证。

研究设计与样本

  • 前瞻性随机试验,2010-2013年完成,纳入118例膀胱癌患者行根治性膀胱切除术/盆腔淋巴结清扫和尿流改道。
  • 存活患者术后中位随访4.9年(IQR 3.9-5.9)。

主要发现

  • 复发风险无差异(HR 1.27;95%CI 0.69-2.36;P=0.4),癌症特异性生存(P=0.4)和总生存(P=0.8)亦无差异。
  • 开放手术组转移部位首次复发风险非显著升高(sHR 2.21;95%CI 0.96-5.12;P=0.064)。
  • 机器人辅助组局部/腹部首次复发风险更高(sHR 0.34;95%CI 0.12-0.93;P=0.035)。

临床怎么用

  • 对于适合根治性膀胱切除术的膀胱癌患者,开放与机器人辅助手术在肿瘤学结局上未见明确差异,但需注意复发模式可能不同。

局限性

  • 试验把握度不足以确定癌症复发、生存结局或复发模式的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Open radical cystectomy (ORC) has proven to be an important component in the treatment of high-risk bladder cancer (BCa). ORC surgical morbidity remains high; therefore, minimally invasive surgical techniques have been introduced in an attempt to improve patient outcomes. OBJECTIVE: To compare cancer outcomes in BCa patients managed with ORC or robotic-assisted radical cystectomy (RARC). DESIGN, SETTING, AND PARTICIPANTS: A prospective, randomized trial was completed between 2010 and 2013. Patients were randomized to ORC/pelvic lymphadenectomy (PLND) or RARC/PLND, with all undergoing open/extracorporeal urinary diversion. Median follow-up was 4.9 (IQR: 3.9-5.9) yr after surgery among surviving patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Secondary outcomes to the trial included recurrence-free, cancer-specific, and overall survival. RESULTS AND LIMITATIONS: The trial randomized 118 patients who underwent RC/PLND and urinary diversion. Sixty were randomized to RARC and 58 to ORC. Four RARC-assigned patients refused randomization and received ORC; however, an intention to treat analysis was performed. No differences were observed in recurrence (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 0.69-2.36; p=0.4) or cancer-specific survival (p=0.4). No difference in overall survival was observed (p=0.8). However, the pattern of first recurrence demonstrated a nonstatistically significant increase in metastatic sites for those undergoing ORC (sub-HR [sHR]: 2.21; 95% CI: 0.96-5.12; p=0.064) and a greater number of local/abdominal sites in the RARC-treated patients (sHR: 0.34; 95% CI: 0.12-0.93; p=0.035). The major limitation to this study is that the trial was not powered to determine differences in cancer recurrences, survival outcomes, or patterns of recurrence. CONCLUSIONS: The secondary outcomes from our randomized trial did not definitively demonstrate differences in cancer outcomes in patients treated with ORC or RARC. However, differences in observed patterns of first recurrence highlight the need for future studies. PATIENT SUMMARY: Of 118 patients randomly assigned to undergo radical cystectomy/pelvic lymphadenectomy and urinary diversion, half were assigned to open surgery and half to robot-assisted techniques. We found no difference in risk of recurring or dying of bladder cancer between the two groups.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bochner BH, Dalbagni G, Marzouk KH, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol. 2018. PMID: 29784190. doi:10.1016/j.eururo.2018.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。